MAPT and Alzheimer disease: Second, therapeutic effects of L-DOPA on tauopathy might be observed in human tau transgenic P301S (PS19) mice, another AD model, and we will therefore investigate the effects of L-DOPA on tau pathology (i.e., tau inclusion and propagation of tau aggregates) in human tau transgenic PS19 mice.